NVE (NVEC) Q4 2026 earnings review
Earnings Accelerate as Core Products Rebound
NVE delivered a robust Q4, successfully shaking off the first-half weakness that plagued the semiconductor industry. Revenue grew 5% YoY to $7.65M, but the real story was operational leverage: Net Income surged 27% YoY to $4.93M (EPS of $1.02). This marks the second consecutive quarter of accelerating earnings growth, driven by a 6% increase in core product sales that more than offset a 19% decline in volatile contract R&D revenue. The company’s completed capacity expansion and strategic focus on medical/industrial markets are paying off, though gross margin compression remains a persistent underlying drag.
🐂 Bull Case
Core product sales grew 6% YoY to $7.40M, building on the recovery that started in Q3. The destocking cycle in the distributor channel appears to be fully in the rearview mirror.
A 5% revenue increase drove a 27% increase in net income, showcasing excellent cost control (SG&A fell 5% YoY) and the inherent operating leverage of NVE's fab model.
🐻 Bear Case
Despite higher volumes, gross margin declined to 77.8% from 79.2% a year ago, likely due to a higher mix of lower-margin distributor sales.
Contract R&D revenue fell 19% YoY just one quarter after surging 335%, highlighting the lumpiness that makes NVE's total revenue difficult to forecast.
⚖️ Verdict: 🟢
Bullish. NVE has successfully navigated an industry downturn, returning to solid top-line growth while delivering outsized earnings expansion. If the new Wafer-Level Chip Scale Packaging capabilities gain traction, the growth trajectory is highly sustainable.
Key Themes
Wafer-Level Chip Scale Packaging (WLCSP) Unlocking Medical Markets
NVE recently completed a multi-year, multi-million dollar equipment expansion, bringing WLCSP capabilities in-house. This allows the company to produce ultra-small sensors (less than 1/1000th of a square inch) with extreme precision. This is a critical driver for penetrating the high-margin implantable medical device and surgical robotics markets, shifting NVE from a simple component supplier to a strategic partner.
Distributor Channel Recovery
Product sales grew 6% YoY in Q4 to $7.40M, confirming that the end of the inventory destocking cycle seen in H1 was not a fluke. Accelerating end-market demand in industrial controls and smart factories has provided the 'wind at their backs' management cited in prior quarters.
Supply Chain De-Risking via Rare Earth-Free Sensors
Macro Theme: NVE is actively capitalizing on geopolitical risks by promoting spintronic sensors that operate with widely available, cheap ferrite magnets instead of Chinese-sourced rare earths. As manufacturers seek to de-risk their supply chains against tariff and trade barrier threats, NVE's high-sensitivity sensors are translating into active design wins.
Gross Margin Compression Despite Volume Gains
A concerning contradiction: Despite the 27% surge in net income and higher factory utilization, Q4 gross margin actually declined to 77.8% from 79.2% a year ago. Management previously attributed margin pressure to a higher mix of lower-margin distributor sales. The inability to push gross margins back above the 80% mark during a volume rebound warrants close monitoring.
Contract R&D Volatility
Contract R&D revenue fell 19% YoY in Q4 to $258K, completely reversing the massive 335% surge seen in Q3. While NVE uses R&D contracts to fund intellectual property development rather than as a primary growth engine, this extreme lumpiness obscures the underlying growth rate of the core business and makes quarterly revenue highly unpredictable.
Defense Segment Uncertainty
The defense business (anti-tamper/PUF) has historically been a drag on recent quarters. While management expressed optimism in Q3 about returning to a 'normal flow,' the lack of clear segment breakdowns in Q4 leaves investors guessing whether defense has actually stabilized or if commercial industrial sales are simply masking continued weakness.
Other KPIs
Accelerating. Up from 58.4% in 25Q4 and 60.1% in 26Q3. Total expenses were slashed to $1.21M from $1.50M a year ago, primarily due to a sharp drop in R&D costs (down 26% YoY). This stringent cost control is the primary reason Net Income grew 5x faster than Revenue.
Stable. Down slightly from $48.0M at the end of FY25, reflecting the heavy capital expenditures made during the year to upgrade fab capabilities. The balance sheet remains bulletproof with zero debt, easily supporting the aggressive $1.00 quarterly dividend.
Guidance
Stable. NVE does not provide forward quantitative revenue or earnings guidance. However, the Board maintained the $1.00 quarterly cash dividend (payable May 29, 2026), signaling continued confidence in the company's cash flow generation despite the heavy CapEx cycle recently completed.
Key Questions
Gross Margin Floor
With gross margins compressing to 77.8% this quarter despite higher product volumes, what is the expected long-term margin profile as distributor sales continue to outpace direct sales?
WLCSP Revenue Ramp
The new Wafer-Level Chip Scale Packaging equipment is now in place. When do you expect these ultra-small sensors to start contributing meaningfully to product revenue, and are they accretive to corporate margins?
Defense Sector Recovery
In Q3, you mentioned expecting a return to 'normal flow' in the lumpy defense business. Did that normalization occur in Q4, or are we still waiting for those procurement cycles to catch up?
MRAM IP Monetization
You've previously noted the intention to license NVE's MRAM IP rather than manufacture high-volume memory chips. What is the status of active licensing discussions with potential partners?